Coya Therapeutics (COYA) Investor presentation summary

Investment highlights and market opportunity

• Focus on ALS, FTD, and Alzheimer's, all with high unmet medical need and large market potential exceeding $10B combined.

• COYA 302 and COYA 303 are novel combination therapies targeting Treg dysfunction, with ongoing and planned Phase 2 studies.

• Strategic partnership with Dr. Reddy's includes up to $700M in milestones and a $10M investment, supporting a cash runway into 2H 2027.

Scientific rationale and therapeutic approach

• Combination therapies based on low-dose IL-2 and CTLA4-Ig (COYA 302) or GLP-1 RA (COYA 303) aim to restore Treg function and rebalance immune homeostasis.

• Validated by Nobel Prize-winning science and independent studies linking Treg dysfunction to neurodegeneration.

• Early clinical data show stabilization or improvement in ALS and FTD patients, with enhanced Treg function and reduced neuroinflammation.

Clinical development and milestones

• COYA 302 ALSTARS Phase 2 in ALS is enrolling, with top-line data expected 1Q 2027; FTD Phase 2a to start 2H 2026.

• Investigator-initiated trials in ALS and FTD demonstrated improved or stabilized clinical scores and increased Treg function.

• COYA 303 for Alzheimer's has shown preclinical efficacy and is preparing for a pre-IND meeting with the FDA in mid-2026.